News
-
- 02.08 2021
-
Cover Story of ASH 2020 | BriSTAR Immunotech Limited's innovative STAR-T is reported at the headlines of the Hematology News, the official journal of the American Society of Hematology
The phase I clinical study of T cell therapy, an innovative STAR technology platform jointly developed by BriSTAR Immunotech Limited and Tsinghua University, is first appeared on the international stage and becomes one of the few studies selected as the oral report at the meeting of ASH 2020.
-
- 12.07 2020
-
Oral Report at ASH 2020 | research data on innovative STAR-T product for the treatment of R/R B-ALL
The research paper entitled “a Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)” independently developed by China Immunotech (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as "BriSTAR Immunotech Limited") is selected as the oral report at the meeting of ASH 2020 after strict review, making a voice on the international stage.
-
- 03.09 2020
-
BriSTAR Immunotech Limited successfully completes the round a financing of 45million Yuan
In January 2020, BriSTAR Immunotech Limited successfully completes round A of financing of 45 million Yuan. This round of financing is led by the Shanghai Jianxin Equity, with joint investments by the Guanghua Venture Capital and the Zhejiang Huacheng Group. Previously, BriSTAR Immunotech Limited also received tens of millions of Yuan of early investment by the Lotus Lake Capital and the QF Capital.